NCT01437618CompletedNot Applicable
FOLFOXIRI Plus Bevacizumab as First-line Treatment for BRAF V600E Mutant Metastatic Colorectal Cancer: a Prospective Evaluation
Azienda Ospedaliero, Universitaria Pisana1 site in 1 country15 target enrollmentStarted: June 2009Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 15
- Locations
- 1
- Primary Endpoint
- Progression-Free Survival
Study Overview
Brief Summary
The purpose of this study is to prospectively verify if FOLFOXIRI plus bevacizumab as first-line treatment could be considered a promising approach to improve the outcome of BRAF mutant metastatic colorectal cancer patients
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologically confirmed colorectal adenocarcinoma;
- •Availability of formalin-fixed paraffin embedded tumor block from primary and/or metastasis;
- •BRAF V600E mutant status of primary colorectal cancer and/or related metastasis;
- •Unresectable and measurable metastatic disease according to RECIST criteria;
- •Male or female, aged > 18 years and < 75 years;
- •ECOG PS < 2 if aged < 71 years;
- •ECOG PS = 0 if aged 71-75 years;
- •Life expectancy of more than 3 months;
- •Adequate haematological function: ANC ≥ 1.5 x 10^9/L; platelets ≥ 100 x 10^9/L, Hb ≥ 9 g/dL;
- •Adequate liver function: serum bilirubin ≤ 1.5 x ULN; alkaline phosphatase and transaminases ≤ 2.5 x ULN (in case of liver metastases ≤ 5 x ULN);
- •Serum creatinine ≤ 1.5 x ULN;
- •Previous adjuvant chemotherapy is allowed if more than 12 months have elapsed between the end of adjuvant therapy and first relapse;
- •At least 6 weeks from prior extended radiotherapy and 4 weeks from surgery;
- •Written informed consent to experimental treatment and molecular analyses.
Exclusion Criteria
- •Presence or history of CNS metastasis;
- •Serious, non-healing wound, ulcer, or bone fracture;
- •Evidence of bleeding diathesis or coagulopathy;
- •Uncontrolled hypertension;
- •Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (CVA) (≤6 months before treatment start), myocardial infarction (≤ 6 months before treatment start), unstable angina, NYHA ≥ grade 2 chronic heart failure (CHF), uncontrolled arrhythmia;
- •Current or recent (within 10 days prior to study treatment start) ongoing treatment with anticoagulants for therapeutic purposes;
- •Chronic, daily treatment with high-dose aspirin (>325 mg/day);
- •Symptomatic peripheral neuropathy ≥ 2 grade NCIC-CTG criteria;
- •Active uncontrolled infections;
- •Treatment with any investigational drug within 30 days prior to enrolment;
- •Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of curatively treated basal and squamous cell carcinoma of the skin or in situ cancer of the cervix;
- •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start;
- •Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome;
- •Fertile women (< 2 years after last menstruation) and men of childbearing potential not willing to use effective means of contraception.
Arms & Interventions
BRAF mutant mCRC
Intervention: FOLFOXIRI plus bevacizumab (Drug)
Outcomes
Primary Outcomes
Progression-Free Survival
Time Frame: About 24-30 months (From treatment initiation to evidence of progression or death from any cause)
Secondary Outcomes
No secondary outcomes reported
Investigators
Alfredo Falcone
Professor Alfredo Falcone
Azienda Ospedaliero, Universitaria Pisana
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral CellsMetastatic Colorectal CancerNCT01640405Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)350
Active, not recruiting
Not Applicable
Phase III study to compare two different chemotherapy treatments to determine whether the first line with the three drugs + bevacizumab followed by a second line with the same regimen may provide better results than treatment with two drugs + bevacizumab is the first and the second treatment lineEUCTR2014-004436-19-ITG.O.N.O.
Active, not recruiting
Phase 3
Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal CancerColorectal CancerNCT04230187Yanhong Deng528
Completed
Phase 2
FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer PatientsMetastatic Colorectal CancerNCT03721653Gruppo Oncologico del Nord-Ovest218
Recruiting
Phase 2
Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two StudyNeoplasm MalignantColon Cancer Stage 4NCT06575127Al-Azhar University60